Former Novo Nordisk CEO Lars Rebien Sørensen would like to see a list of objective criteria for where EMA will be placed after Brexit and warns about what might happen if the agency ends up the wrong place.
BY METTE MANDRUP Offentliggjort 21.02.17 kl. 13:09
Log ind for at læse artikler
Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.
Novo Nordisk’s US unit has struck a deal with CVS Health for a new savings program that will give some patients up to 80 percent reduction on some of the group’s insulin products. It thus looks like times are changing in the Denmark-based insulin giant.
The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.
Thanks to a successful gamble on one particular niche, Denmark’s Gubra has managed to quadruple its employee base in just a few years. The two-pronged business is set to expand significantly in the future.
Although its asset value and net result both dipped significantly in 2016, the new CEO of Novo A/S, Kasim Kutay, is very optimistic on behalf of the company. The long-term trend looks good, he says, and the company is ready to increase investments and bridge the gap between two of its units.
Danish biotech Saniona is ready to initiate phase II studies of its lead candidate in a rare disease that leads to obesity and type 2 diabetes. The company aims to add additional endpoints to the study.
The world’s largest hearing device dealer, Amplifon, expresses concern over the entry into the retail market of manufacturers such as William Demant. GN Resound, on the other hand, receives praise and is expected to form even closer ties to its Italian collaborator.
København har fået endnu en konkurrent om at overtage det Europæiske Lægemiddelagentur, når Storbritannien melder sig ud af EU. Denne gang er det et land, som argumenterer for, at det ikke har et agentur i forvejen.
Novo Nordisk har fået en positiv anbefaling om godkendelse af et nyt lægemiddel mod blødersygdommen hæmofili B af et ekspertpanel under de europæiske lægemiddelmyndighder. En ansøgning er også på bordet i USA.